Clin2
NCT07661966Possibly a fitNot yet recruiting

Bright light therapy for melanoma or lung cancer patients starting immunotherapy

Melanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)

Part of Cancer, Lungs & breathing, Skin clinical trials.

This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced melanoma or non-small cell lung cancer that can't be removed with surgery.
  • You are about to start your first immunotherapy treatment (like Keytruda or a combination).
  • You are 18 or older and can use the internet at home.
  • You are not using melatonin or prescription sleep aids, and do not have certain eye conditions.
  • You do not have bipolar disorder, recent psychosis, or poorly controlled seizures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07376512Not yet recruiting
Blood test to predict immunotherapy response in lung cancer and melanoma

This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.

Besançon
NCT05737732Recruiting
Testing ambient light for multiple myeloma patients

This study looks at whether using a special kind of everyday light (called ambient light) can help people with multiple myeloma as they prepare for their first stem cell transplant. It may be aiming to improve comfort or recovery by affecting sleep and the body’s natural signals from light.

New York, New York
NCT05498792Recruiting· Early Phase 1
Trial testing CBL0137 with two immunotherapy drugs for melanoma

This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.

Philadelphia, Pennsylvania
NCT07628894Not yet recruiting· Phase 1
Light therapy to boost immune treatment for advanced melanoma

This study tests whether special light therapy timed to your body's natural rhythms can improve how well your immune cells (called TIL therapy) fight advanced melanoma. You must already be enrolled in standard TIL therapy and have progressed despite previous immunotherapy.

Duarte, California
NCT07574047Not yet recruiting· Phase 2
Timing immunotherapy with body rhythms for advanced melanoma

This study tests whether giving immunotherapy (medicines that help your immune system fight cancer) at specific times of day—aligned with your body's natural rhythms—works better for advanced melanoma. Researchers will randomly assign you to receive treatment either on a timed schedule or a standard schedule.

Fribourg, Canton of Fribourg
NCT05875870Recruiting
Bright light and exercise program for lung or esophageal cancer

This trial tests whether a structured bright-light exposure routine combined with a specific exercise program can help people with newly diagnosed lung or esophageal cancer. You may be eligible if you’re in early-to-middle cancer stages and able to safely participate in walking-based activities.

Taipei City, Taipei

Hear when a new Melanoma (Skin Cancer) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.